Echosens 在 2022 年 AASLD 肝臟會議上展示了強有力的研究：無創

StephenW

Echosens 在 2022 年 AASLD 肝臟會議上展示了強有力的研究：無創 FibroScan® 技術被公認為優化肝臟健康管理的關鍵組成部分
東部夏令時間 2022 年 11 月 1 日上午 08:00

馬薩諸塞州巴黎和沃爾瑟姆--(BUSINESS WIRE)--(美國商業資訊)--提供肝臟診斷解決方案的高科技公司 Echosens 很高興地宣布其將在即將舉行的美國肝病研究協會 (AASLD) 肝臟會議上強勢亮相， 2022 年 11 月 4 日至 8 日，在華盛頓特區。基於 FibroScan® 的解決方案在 130 多篇摘要中被引用，其中包括 17 篇口頭報告。肝臟會議匯集了來自世界各地的臨床醫生、同事和科學家，交流最新研究信息，討論肝臟治療和移植的新進展，並與肝病學領域的領先專家建立聯繫。

    “我們很高興 FibroScan 連續獲得全球肝病學最重要會議之一的認可”
    發推文

Echosens 集團首席執行官 Dominque Legros 表示：“我們很高興 FibroScan 在全球肝病學領域最重要的會議之一中連續獲得認可。” “FibroScan 是一種快速、無痛的檢查，可在不到 10 分鐘的時間內完成，以便在護理點立即提供結果。通過振動控制瞬態彈性成像（VCTE 的 LSM）驗證肝臟硬度測量是改善風險分層和加強臨床決策的無創測試的基石。”

非酒精性脂肪性肝病 (NAFLD) 目前影響約 37% 的成年人，無症狀，在初級保健或糖尿病診所很少被診斷出來。如果不加以解決，NAFLD 會導致更嚴重的並發症，例如非酒精性脂肪性肝炎 (NASH)、纖維化和肝硬化。早期診斷是阻止甚至逆轉肝病進展的關鍵因素。鑑於早期疾病識別和管理的臨床和成本控制優勢，無創 FibroScan 技術是醫學專家識別患 NAFLD 高風險患者的重要工具。

“在與全球肝病流行的鬥爭中，Echosens 很自豪地宣布進一步驗證我們的 FibroScan 技術在治療晚期慢性肝病患者方面的有效性，”Echosens 北美首席執行官 Jon Gingrich 說。 “我們將繼續創新和改善對無症狀、診斷不足的慢性肝病的管理。”

關於迴聲

作為該領域的先驅，Echosens 使用 FibroScan® 顯著改變了肝臟評估的實踐，FibroScan® 是肝臟健康綜合管理的非侵入性解決方案。 FibroScan® 在全球範圍內得到認可，並得到超過 3,500 份同行評審出版物和 160 份國際指南的驗證。 Echosens 已在 100 多個國家/地區提供 FibroScan®，使全球數百萬次肝臟檢查成為可能。 https://www.echosens.com/

StephenW

Echosens Presents Robust Research at 2022 AASLD Liver Meeting: Noninvasive FibroScan® Technology Recognized as Critical Component to Optimize Liver Health Management
November 01, 2022 08:00 AM Eastern Daylight Time

PARIS & WALTHAM, Mass.--(BUSINESS WIRE)--Echosens, a high-technology company offering liver diagnostic solutions, is pleased to announce its strong presence at the upcoming American Association for the Study of Liver Diseases (AASLD) Liver Meeting, Nov. 4-8, 2022, in Washington, D.C. FibroScan®-based solutions are referenced in over 130 abstracts including 17 oral presentations. The Liver Meeting brings together clinicians, associates and scientists from around the world to exchange information on the latest research, discuss new developments in liver treatment and transplantation and network with leading experts in the field of hepatology.

    “We are gratified that FibroScan is consecutively recognized at one of the most important meetings in hepatology worldwide”
    Tweet this

“We are gratified that FibroScan is consecutively recognized at one of the most important meetings in hepatology worldwide,” says Dominque Legros, Echosens Group CEO. “FibroScan is a quick and painless exam that can be performed in less than 10 minutes to provide immediate results at point-of-care. Validation of liver stiffness measurement by vibration controlled transient elastography (LSM by VCTE) serves as the cornerstone of noninvasive tests to improve risk stratification and enhance clinical decision-making.”

Nonalcoholic fatty liver disease (NAFLD) currently affects approximately 37% of adults, is asymptomatic and is infrequently diagnosed in primary care or diabetology clinics. When left unaddressed, NAFLD can lead to more serious complications, such as non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis. Early diagnosis is a key factor in halting or even reversing the progression of liver disease. Given the clinical and cost-containment benefits of early disease identification and management, noninvasive FibroScan technology is an important tool for medical specialists in identifying patients at high risk of developing NAFLD.

“In the battle against a worldwide liver disease epidemic, Echosens is proud to announce further validation for the effectiveness of our FibroScan technologies for the management of patients with advanced chronic liver disease,” says Jon Gingrich, CEO, Echosens, North America. “We will continue to innovate and improve the management of silent, underdiagnosed chronic liver disease.”

About Echosens

Pioneer in its field, Echosens significantly changed the practice of liver assessment with FibroScan®, the non-invasive solution for comprehensive management of liver health. FibroScan® is recognized worldwide and validated by over 3,500 peer reviewed publications and 160 international guidelines. Echosens has made FibroScan® available in over 100+ countries enabling millions of liver examinations worldwide. https://www.echosens.com/